[{"id":"18709fb5-d496-4979-9052-5f591bc2f04d","acronym":"","url":"https://clinicaltrials.gov/study/NCT06949033","created_at":"2025-06-28T16:10:58.051Z","updated_at":"2025-06-28T16:10:58.051Z","phase":"Phase 3","brief_title":"Neoadjuvant Cadonilimab Combined With Perioperative Oxaliplatin Plus S1 for Diffuse or Mixed Type of Locally Advanced Gastric/Gastroesophageal Junction Adenocarcinoma","source_id_and_acronym":"NCT06949033","lead_sponsor":"Zuoyi Jiao","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tyvyt (sintilimab) • AiTan (rivoceranib) • oxaliplatin • Kaitanni (cadonilimab)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 668","initiation":"Initiation: 05/15/2025","start_date":" 05/15/2025","primary_txt":" Primary completion: 12/31/2028","primary_completion_date":" 12/31/2028","study_txt":" Completion: 12/31/2030","study_completion_date":" 12/31/2030","last_update_posted":"2025-04-29"},{"id":"722a2a86-9fad-4d71-874a-87f0351a5eef","acronym":"","url":"https://clinicaltrials.gov/study/NCT06925243","created_at":"2025-06-28T16:10:56.066Z","updated_at":"2025-06-28T16:10:56.066Z","phase":"Phase 3","brief_title":"Neoadjuvant Apatinib Combined With Sintilimab and Perioperative SOX Versus Neoadjuvant Sintilimab Combined With Perioperative SOX for Intestinal Type of Locally Advanced Gastric/Gastroesophageal Junction Adenocarcinoma","source_id_and_acronym":"NCT06925243","lead_sponsor":"Zuoyi Jiao","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tyvyt (sintilimab) • AiTan (rivoceranib) • oxaliplatin"],"overall_status":"Recruiting","enrollment":" Enrollment 682","initiation":"Initiation: 04/15/2025","start_date":" 04/15/2025","primary_txt":" Primary completion: 12/31/2027","primary_completion_date":" 12/31/2027","study_txt":" Completion: 12/31/2030","study_completion_date":" 12/31/2030","last_update_posted":"2025-04-22"},{"id":"6d7c8fa9-67d2-4bc9-bef1-9bdadb373194","acronym":"","url":"https://clinicaltrials.gov/study/NCT04863430","created_at":"2021-04-28T12:52:46.950Z","updated_at":"2025-02-25T13:49:08.094Z","phase":"Phase 2","brief_title":"Apatinib with Oxaliplatin and S-1 Treatment for Advanced Hepatoid Adenocarcinoma of the Stomach","source_id_and_acronym":"NCT04863430","lead_sponsor":"Peking University","biomarkers":" HER-2 • GPC3 • SALL4","pipe":" | ","alterations":" HER-2 positive • HER-2 negative","tags":["HER-2 • GPC3 • SALL4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AiTan (rivoceranib) • oxaliplatin • Teysuno (gimeracil/oteracil/tegafur)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 05/11/2021","start_date":" 05/11/2021","primary_txt":" Primary completion: 07/06/2023","primary_completion_date":" 07/06/2023","study_txt":" Completion: 07/06/2023","study_completion_date":" 07/06/2023","last_update_posted":"2025-02-21"},{"id":"b3d0abdf-0279-4d36-aa6d-69fe2e62ba80","acronym":"SHR-1316-SCLC-LN-001","url":"https://clinicaltrials.gov/study/NCT06480864","created_at":"2025-02-26T07:35:04.037Z","updated_at":"2025-02-26T07:35:04.037Z","phase":"","brief_title":"Adebrelimab Plus Apatinib for Maintenance Therapy of Extensive Stage Small Cell Lung Cancer","source_id_and_acronym":"NCT06480864 - SHR-1316-SCLC-LN-001","lead_sponsor":"Yunpeng Liu","biomarkers":" PD-L1 • IL6 • IL10","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1 • IL6 • IL10"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • carboplatin • AiTan (rivoceranib) • etoposide IV • AiRuiLi (adebrelimab)"],"overall_status":"Recruiting","enrollment":" Enrollment 38","initiation":"Initiation: 08/09/2024","start_date":" 08/09/2024","primary_txt":" Primary completion: 08/01/2025","primary_completion_date":" 08/01/2025","study_txt":" Completion: 08/01/2026","study_completion_date":" 08/01/2026","last_update_posted":"2025-01-06"},{"id":"5ab5758f-ded0-479b-83dd-b16b495d0f1a","acronym":"FASCINATE-N","url":"https://clinicaltrials.gov/study/NCT05582499","created_at":"2022-10-17T13:56:00.115Z","updated_at":"2025-02-25T12:29:07.250Z","phase":"Phase 2","brief_title":"Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy","source_id_and_acronym":"NCT05582499 - FASCINATE-N","lead_sponsor":"Fudan University","biomarkers":" HER-2 • PGR • CD8 • FOXC1","pipe":"","alterations":" ","tags":["HER-2 • PGR • CD8 • FOXC1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • carboplatin • Perjeta (pertuzumab) • AiRuiKa (camrelizumab) • AiTan (rivoceranib) • Irene (pyrotinib) • albumin-bound paclitaxel • cyclophosphamide • letrozole • epirubicin • trastuzumab rezetecan (SHR-A1811) • AiRuiYi (fluzoparib) • AiRuiKang (dalpiciclib) • goserelin acetate • famitinib (SHR 1020) • AiRuiLi (adebrelimab) • tizetatug rezetecan (SHR-A1921)"],"overall_status":"Recruiting","enrollment":" Enrollment 716","initiation":"Initiation: 11/01/2022","start_date":" 11/01/2022","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 09/01/2025","study_completion_date":" 09/01/2025","last_update_posted":"2024-12-27"},{"id":"6ca03c28-cf88-4ab8-8a2b-e94506f71d40","acronym":"","url":"https://clinicaltrials.gov/study/NCT04701060","created_at":"2025-02-26T10:39:27.170Z","updated_at":"2025-02-26T10:39:27.170Z","phase":"Phase 2","brief_title":"Camrelizumab Combined With Apatinib for Perioperative Treatment of Resectable Primary Hepatocellular Carcinoma","source_id_and_acronym":"NCT04701060","lead_sponsor":"Tianjin Medical University Cancer Institute and Hospital","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AiRuiKa (camrelizumab) • AiTan (rivoceranib)"],"overall_status":"Completed","enrollment":" Enrollment 31","initiation":"Initiation: 01/26/2021","start_date":" 01/26/2021","primary_txt":" Primary completion: 03/04/2024","primary_completion_date":" 03/04/2024","study_txt":" Completion: 10/04/2024","study_completion_date":" 10/04/2024","last_update_posted":"2024-12-03"},{"id":"eedcfd8a-207e-40d0-9c7b-407fde95960b","acronym":"","url":"https://clinicaltrials.gov/study/NCT03982485","created_at":"2021-01-18T19:34:24.357Z","updated_at":"2024-07-02T16:35:06.857Z","phase":"Phase 2","brief_title":"Combination Neoadjuvant Chemotherapy With or Without Apatinib for HER2 Negative Breast Cancer","source_id_and_acronym":"NCT03982485","lead_sponsor":"RenJi Hospital","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • paclitaxel • AiTan (rivoceranib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 196","initiation":"Initiation: 10/16/2018","start_date":" 10/16/2018","primary_txt":" Primary completion: 03/29/2023","primary_completion_date":" 03/29/2023","study_txt":" Completion: 03/29/2031","study_completion_date":" 03/29/2031","last_update_posted":"2024-04-30"},{"id":"c23452ee-9413-4c76-bc52-df1b531d2d45","acronym":"","url":"https://clinicaltrials.gov/study/NCT04581473","created_at":"2021-03-09T09:00:08.732Z","updated_at":"2024-07-02T16:35:16.030Z","phase":"Phase 1/2","brief_title":"Study to Evaluate the Efficacy, Safety and Pharmacokinetics of CT041 Autologous CAR T-cell Injection","source_id_and_acronym":"NCT04581473","lead_sponsor":"CARsgen Therapeutics Co., Ltd.","biomarkers":" HER-2 • CLDN18","pipe":" | ","alterations":" HER-2 expression • CLDN18.2 positive","tags":["HER-2 • CLDN18"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 expression • CLDN18.2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e paclitaxel • AiTan (rivoceranib) • irinotecan • satricabtagene autoleucel (CT041)"],"overall_status":"Recruiting","enrollment":" Enrollment 192","initiation":"Initiation: 10/23/2020","start_date":" 10/23/2020","primary_txt":" Primary completion: 06/30/2024","primary_completion_date":" 06/30/2024","study_txt":" Completion: 06/30/2038","study_completion_date":" 06/30/2038","last_update_posted":"2024-03-06"},{"id":"15519149-5911-4354-ba1c-aa8e98df5dca","acronym":"","url":"https://clinicaltrials.gov/study/NCT03190239","created_at":"2021-01-18T15:43:47.591Z","updated_at":"2024-07-02T16:35:17.221Z","phase":"Phase 2","brief_title":"Efficacy and Safety of Maintenance Apatinib Combined With Pemetrexed in Advanced Non-squamous Non-small Cell Lung Cancer Patients","source_id_and_acronym":"NCT03190239","lead_sponsor":"Xinqiao Hospital of Chongqing","biomarkers":" EGFR • ALK","pipe":" | ","alterations":" EGFR mutation • ALK positive • ALK fusion • ALK mutation","tags":["EGFR • ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • ALK positive • ALK fusion • ALK mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AiTan (rivoceranib) • pemetrexed"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 07/15/2017","start_date":" 07/15/2017","primary_txt":" Primary completion: 07/30/2020","primary_completion_date":" 07/30/2020","study_txt":" Completion: 07/30/2020","study_completion_date":" 07/30/2020","last_update_posted":"2024-02-28"},{"id":"afe5eda5-b0b2-4528-9023-e2c1d7118027","acronym":"","url":"https://clinicaltrials.gov/study/NCT05905887","created_at":"2023-06-15T17:08:41.962Z","updated_at":"2024-07-02T16:35:17.151Z","phase":"Phase 2","brief_title":"Rivoceranib Plus Paclitaxel in Patients With Gastrointestinal Stromal Tumor","source_id_and_acronym":"NCT05905887","lead_sponsor":"Asan Medical Center","biomarkers":" KIT • PDGFRA • ANO1","pipe":" | ","alterations":" KIT mutation","tags":["KIT • PDGFRA • ANO1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KIT mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e paclitaxel • imatinib • sunitinib • AiTan (rivoceranib) • Stivarga (regorafenib)"],"overall_status":"Recruiting","enrollment":" Enrollment 48","initiation":"Initiation: 09/06/2023","start_date":" 09/06/2023","primary_txt":" Primary completion: 08/31/2026","primary_completion_date":" 08/31/2026","study_txt":" Completion: 12/31/2026","study_completion_date":" 12/31/2026","last_update_posted":"2024-02-28"},{"id":"fc8f9f8c-9d3c-4931-98d3-4b6c2d9d3361","acronym":"","url":"https://clinicaltrials.gov/study/NCT03792503","created_at":"2021-01-18T18:45:02.069Z","updated_at":"2024-07-02T16:35:17.437Z","phase":"Phase 4","brief_title":"Pemetrexed Plus Apatinib Maintenance Treatment in Patients With Non-squamous Non-small Cell Lung Cancer Patients Who Have Not Progressed After 4 Cycles of Induction Chemotherapy of Pemetrexed in Combination With Platinum-based Regimen","source_id_and_acronym":"NCT03792503","lead_sponsor":"Xinqiao Hospital of Chongqing","biomarkers":" EGFR • ALK","pipe":" | ","alterations":" EGFR mutation • ALK positive • ALK fusion • ALK mutation","tags":["EGFR • ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • ALK positive • ALK fusion • ALK mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AiTan (rivoceranib) • pemetrexed"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 02/01/2019","start_date":" 02/01/2019","primary_txt":" Primary completion: 02/01/2020","primary_completion_date":" 02/01/2020","study_txt":" Completion: 02/01/2022","study_completion_date":" 02/01/2022","last_update_posted":"2024-02-28"},{"id":"aa38eeda-5483-4291-b2f6-f2732467a0db","acronym":"SYSKY-2023-1016-01","url":"https://clinicaltrials.gov/study/NCT06255392","created_at":"2024-02-14T01:28:08.463Z","updated_at":"2024-07-02T16:35:19.550Z","phase":"Phase 3","brief_title":"Randomized, Open, Controlled, Multicenter Phase III Clinical Study of Fluzoparib in Combination With Apatinib Versus Investigator-Selected Chemotherapy for HRD-Positive/HER2-negative Advanced Breast Cancer","source_id_and_acronym":"NCT06255392 - SYSKY-2023-1016-01","lead_sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","biomarkers":" BRCA","pipe":"","alterations":" ","tags":["BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gemcitabine • paclitaxel • AiTan (rivoceranib) • capecitabine • Halaven (eribulin mesylate) • AiRuiYi (fluzoparib) • Navelbine oral (vinorelbine tartrate oral)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 200","initiation":"Initiation: 02/01/2024","start_date":" 02/01/2024","primary_txt":" Primary completion: 03/01/2031","primary_completion_date":" 03/01/2031","study_txt":" Completion: 03/01/2031","study_completion_date":" 03/01/2031","last_update_posted":"2024-02-13"},{"id":"47481f7c-4d73-4ee0-9312-6b63c4d1442d","acronym":"BCTOP-L-M05","url":"https://clinicaltrials.gov/study/NCT05594095","created_at":"2022-10-26T13:56:12.698Z","updated_at":"2024-07-02T16:35:20.799Z","phase":"Phase 2","brief_title":"SNF Platform Study of HR+/ HER2-advanced Breast Cancer","source_id_and_acronym":"NCT05594095 - BCTOP-L-M05","lead_sponsor":"Fudan University","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" ER positive • HR positive • HER-2 amplification • HER-2 negative • PGR positive","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HR positive • HER-2 amplification • HER-2 negative • PGR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e sorafenib • everolimus • AiRuiKa (camrelizumab) • AiTan (rivoceranib) • capecitabine • albumin-bound paclitaxel • fulvestrant • exemestane • trastuzumab rezetecan (SHR-A1811) • AiRuiYi (fluzoparib) • AiRuiKang (dalpiciclib) • goserelin acetate • famitinib (SHR 1020)"],"overall_status":"Recruiting","enrollment":" Enrollment 140","initiation":"Initiation: 12/30/2022","start_date":" 12/30/2022","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 12/01/2026","study_completion_date":" 12/01/2026","last_update_posted":"2024-02-06"},{"id":"8f51155f-9935-4d7a-a804-14d327bef42c","acronym":"BCTOP-L-M04","url":"https://clinicaltrials.gov/study/NCT05759572","created_at":"2023-03-08T17:01:38.073Z","updated_at":"2024-07-02T16:35:20.712Z","phase":"Phase 2","brief_title":"Apatinib With CDK4/6 Inhibitor and Endocrine Therapy in HR+/ HER2- Advanced Breast Cancer","source_id_and_acronym":"NCT05759572 - BCTOP-L-M04","lead_sponsor":"Fudan University","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" ER positive • HR positive • HER-2 negative • PGR positive","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HR positive • HER-2 negative • PGR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AiTan (rivoceranib) • fulvestrant • AiRuiKang (dalpiciclib)"],"overall_status":"Recruiting","enrollment":" Enrollment 145","initiation":"Initiation: 02/01/2023","start_date":" 02/01/2023","primary_txt":" Primary completion: 11/01/2025","primary_completion_date":" 11/01/2025","study_txt":" Completion: 06/01/2027","study_completion_date":" 06/01/2027","last_update_posted":"2024-02-06"},{"id":"09fc7827-ede0-47b8-bfad-87886f2f2991","acronym":"","url":"https://clinicaltrials.gov/study/NCT04714190","created_at":"2021-01-19T20:53:05.479Z","updated_at":"2024-07-02T16:35:25.513Z","phase":"Phase 3","brief_title":"A Study of RC48-ADC in Local Advanced or Metastatic Gastric Cancer With the HER2-Overexpression","source_id_and_acronym":"NCT04714190","lead_sponsor":"RemeGen Co., Ltd.","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 overexpression","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e paclitaxel • AiTan (rivoceranib) • irinotecan • Aidixi (disitamab vedotin)"],"overall_status":"Recruiting","enrollment":" Enrollment 351","initiation":"Initiation: 03/24/2021","start_date":" 03/24/2021","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 06/30/2025","study_completion_date":" 06/30/2025","last_update_posted":"2023-12-21"},{"id":"ffae4e87-96f3-49a9-8043-f936b544b213","acronym":"","url":"https://clinicaltrials.gov/study/NCT05069857","created_at":"2021-10-06T12:54:05.469Z","updated_at":"2024-07-02T16:35:28.377Z","phase":"Phase 2","brief_title":"Neoadjuvant Personalized Anti-PD-1 and Anti-VEGFR Therapy in OSCC Patients","source_id_and_acronym":"NCT05069857","lead_sponsor":"Shanghai Jiao Tong University School of Medicine","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AiRuiKa (camrelizumab) • AiTan (rivoceranib)"],"overall_status":"Recruiting","enrollment":" Enrollment 46","initiation":"Initiation: 09/01/2021","start_date":" 09/01/2021","primary_txt":" Primary completion: 08/30/2024","primary_completion_date":" 08/30/2024","study_txt":" Completion: 06/30/2028","study_completion_date":" 06/30/2028","last_update_posted":"2023-11-22"},{"id":"7fe8877d-c34b-47ad-b49c-85b43f276263","acronym":"","url":"https://clinicaltrials.gov/study/NCT06099821","created_at":"2023-10-25T19:14:05.391Z","updated_at":"2024-07-02T16:35:31.498Z","phase":"Phase 2","brief_title":"KN046 Plus Regorafenib or Apatinib in MSI-H Digestive System Cancers Resistant to PD-1/PD-L1 Blockade","source_id_and_acronym":"NCT06099821","lead_sponsor":"Peking University Cancer Hospital \u0026 Institute","biomarkers":" PD-L1 • MSI","pipe":" | ","alterations":" MSI-H/dMMR","tags":["PD-L1 • MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AiTan (rivoceranib) • Stivarga (regorafenib) • erfonrilimab (KN046)"],"overall_status":"Recruiting","enrollment":" Enrollment 39","initiation":"Initiation: 10/25/2023","start_date":" 10/25/2023","primary_txt":" Primary completion: 12/31/2026","primary_completion_date":" 12/31/2026","study_txt":" Completion: 12/31/2026","study_completion_date":" 12/31/2026","last_update_posted":"2023-10-26"},{"id":"b43c2ea2-4586-458a-901f-49a09058d132","acronym":"","url":"https://clinicaltrials.gov/study/NCT04074564","created_at":"2021-01-18T19:57:25.307Z","updated_at":"2024-07-02T16:35:32.118Z","phase":"Phase 1","brief_title":"MASCT-I Combined With Apatinib and/or Camrelizumab in the Treatment of Bone and Soft Tissue Sarcoma","source_id_and_acronym":"NCT04074564","lead_sponsor":"HRYZ Biotech Co.","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AiRuiKa (camrelizumab) • AiTan (rivoceranib)"],"overall_status":"Recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 11/22/2019","start_date":" 11/22/2019","primary_txt":" Primary completion: 08/07/2024","primary_completion_date":" 08/07/2024","study_txt":" Completion: 12/05/2024","study_completion_date":" 12/05/2024","last_update_posted":"2023-10-23"},{"id":"74d0474d-8a4d-4196-856a-9f95d19d924e","acronym":"BIOVAS","url":"https://clinicaltrials.gov/study/NCT04072042","created_at":"2021-01-18T19:56:06.263Z","updated_at":"2024-07-02T16:35:35.004Z","phase":"Phase 2","brief_title":"BIOmarker Driven Trial of VEGFR2 Inhibitor in Advanced Sarcoma","source_id_and_acronym":"NCT04072042 - BIOVAS","lead_sponsor":"Ruijin Hospital","biomarkers":" KDR • CSF1R","pipe":"","alterations":" ","tags":["KDR • CSF1R"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AiTan (rivoceranib)"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 08/31/2019","start_date":" 08/31/2019","primary_txt":" Primary completion: 02/25/2024","primary_completion_date":" 02/25/2024","study_txt":" Completion: 05/25/2024","study_completion_date":" 05/25/2024","last_update_posted":"2023-10-03"},{"id":"8a38e0cd-a975-482e-8cc1-cd10a578e9bc","acronym":"","url":"https://clinicaltrials.gov/study/NCT05942573","created_at":"2023-07-12T15:08:58.809Z","updated_at":"2024-07-02T16:35:43.331Z","phase":"Phase 2","brief_title":"Continuation of Serplulimab Plus Chemotherapy After First Progression in Advanced Gastric or Gastro-oesophageal Junction Adenocarcinoma: an Open-label, Randomised Phase II Trial","source_id_and_acronym":"NCT05942573","lead_sponsor":"Tianjin Medical University Cancer Institute and Hospital","biomarkers":" HER-2 • PD-L1","pipe":" | ","alterations":" HER-2 negative • PD-L1 negative","tags":["HER-2 • PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • PD-L1 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e paclitaxel • AiTan (rivoceranib) • Cyramza (ramucirumab) • Hetronifly (serplulimab)"],"overall_status":"Recruiting","enrollment":" Enrollment 107","initiation":"Initiation: 12/24/2022","start_date":" 12/24/2022","primary_txt":" Primary completion: 10/01/2023","primary_completion_date":" 10/01/2023","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2023-07-12"},{"id":"b17610a4-7f1e-4ca3-bde1-2677610463ed","acronym":"","url":"https://clinicaltrials.gov/study/NCT05932264","created_at":"2023-07-06T16:10:07.113Z","updated_at":"2024-07-02T16:35:43.864Z","phase":"Phase 2","brief_title":"Apatinib and Fluzoparib With or Without Adebrelimab in Previously-treated TP53-mutant Advanced Non-small Cell Lung Cancer","source_id_and_acronym":"NCT05932264","lead_sponsor":"Sun Yat-sen University","biomarkers":" EGFR • BRAF • ALK • TP53 • ROS1","pipe":" | ","alterations":" TP53 mutation • ALK positive • TP53 R175H • TP53 R248Q • TP53 Y220C • TP53 R273H • TP53 R273C","tags":["EGFR • BRAF • ALK • TP53 • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • ALK positive • TP53 R175H • TP53 R248Q • TP53 Y220C • TP53 R273H • TP53 R273C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AiTan (rivoceranib) • AiRuiYi (fluzoparib) • AiRuiLi (adebrelimab)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 07/01/2023","start_date":" 07/01/2023","primary_txt":" Primary completion: 07/01/2024","primary_completion_date":" 07/01/2024","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2023-07-06"},{"id":"94dadb9d-e38a-476f-85a6-c8f47bed7586","acronym":"","url":"https://clinicaltrials.gov/study/NCT05889871","created_at":"2023-06-05T14:06:47.924Z","updated_at":"2024-07-02T16:35:46.547Z","phase":"Phase 3","brief_title":"A Randomized, Controlled, Open-label Clinical Trial of Adjuvant Intensive Therapy for HR+/ HER2-SNF4 Early Breast Cancer","source_id_and_acronym":"NCT05889871","lead_sponsor":"Fudan University","biomarkers":" HER-2 • ER","pipe":" | ","alterations":" ER positive • HER-2 negative","tags":["HER-2 • ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e tamoxifen • AiTan (rivoceranib)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 916","initiation":"Initiation: 06/01/2023","start_date":" 06/01/2023","primary_txt":" Primary completion: 06/01/2026","primary_completion_date":" 06/01/2026","study_txt":" Completion: 06/01/2026","study_completion_date":" 06/01/2026","last_update_posted":"2023-06-05"},{"id":"bcbbe910-f302-4cdb-8a25-ddb9bd268bb7","acronym":"","url":"https://clinicaltrials.gov/study/NCT05447702","created_at":"2022-07-07T16:57:15.470Z","updated_at":"2024-07-02T16:35:47.463Z","phase":"Phase 2","brief_title":"Study of Camrelizumab Plus Apatinib and Chemotherapy as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC)","source_id_and_acronym":"NCT05447702","lead_sponsor":"West China Hospital","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 expression • PGR expression","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 expression • PGR expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AiRuiKa (camrelizumab) • AiTan (rivoceranib) • albumin-bound paclitaxel • cyclophosphamide • epirubicin"],"overall_status":"Recruiting","enrollment":" Enrollment 35","initiation":"Initiation: 11/01/2022","start_date":" 11/01/2022","primary_txt":" Primary completion: 12/31/2023","primary_completion_date":" 12/31/2023","study_txt":" Completion: 12/31/2026","study_completion_date":" 12/31/2026","last_update_posted":"2023-05-22"},{"id":"e0a33276-bab6-4059-9c51-653bc69e5a62","acronym":"","url":"https://clinicaltrials.gov/study/NCT04609176","created_at":"2021-01-19T20:32:04.502Z","updated_at":"2024-07-02T16:35:49.961Z","phase":"Phase 2","brief_title":"Study of Camrelizumab (SHR-1210) and Apatinb Based Therapies for Alpha-fetoprotein (AFP)-Producing Gastric Cancer or Gastroesophageal Junction Adenocarcinoma","source_id_and_acronym":"NCT04609176","lead_sponsor":"Peking University","biomarkers":" PD-L1 • AFP","pipe":"","alterations":" ","tags":["PD-L1 • AFP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AiRuiKa (camrelizumab) • AiTan (rivoceranib) • oxaliplatin"],"overall_status":"Recruiting","enrollment":" Enrollment 64","initiation":"Initiation: 11/18/2020","start_date":" 11/18/2020","primary_txt":" Primary completion: 12/31/2023","primary_completion_date":" 12/31/2023","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2023-04-21"}]